Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07301333

A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects

A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.

Conditions

Interventions

TypeNameDescription
DRUGHRS-6257HRS-6257
DRUGplaceboplacebo

Timeline

Start date
2025-12-30
Primary completion
2026-05-01
Completion
2026-05-01
First posted
2025-12-24
Last updated
2026-04-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07301333. Inclusion in this directory is not an endorsement.